ScanSource (SCSC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
26 Oct, 2026Executive summary
2026 annual meeting scheduled for Dec. 8, 2026, at 9:00 a.m. EST in Greenville, South Carolina; voting deadline Dec. 7, 2026, at 11:59 p.m. ET.
Shareholders will vote on seven director nominees, executive compensation, and ratification of Deloitte & Touche LLP for FY ending June 30, 2027.
Voting matters and shareholder proposals
Board recommends voting For all seven director nominees and the advisory vote on named executive officer compensation.
Board recommends ratifying Deloitte & Touche LLP as independent registered public accounting firm for FY ending June 30, 2027.
Brokers may vote routine matters at their discretion if voting instructions are not received at least 10 days before the meeting; shareholder instructions received before the meeting will be followed.
Board of directors and corporate governance
Director nominees are Michael L. Baur, Frank E. Emory, Jr., Charles A. Mathis, Vernon J. Nagel, Dorothy F. Ramoneda, Jeffrey R. Rodek, and Elizabeth O. Temple; the Board recommends For each nominee.
Latest events from ScanSource
- Sales rose 30.1%, but margins and earnings fell; FY27 outlook increased.SCSC
Q1 2027 - Growth, MicroAge integration and longer-term executive incentives headline the proxy.SCSC
Proxy filing - Recurring revenue and strategic M&A drive margin expansion and sustainable growth.SCSC
Investor presentation - Strong Q4 and FY results, with MicroAge acquisition set to drive further margin and sales growth.SCSC
Q4 2026 - Recurring revenue and margin expansion drive growth, supported by disciplined capital allocation.SCSC
Investor presentation - Quarterly sales up 8.8% to $766.8M, strong cash flow, margin gains, and new business initiatives.SCSC
Q3 2026 - Recurring revenues and disciplined capital allocation drive margin growth and efficiency.SCSC
47th Annual Raymond James Institutional Investor Conference - Q2 FY26 saw 2.5% sales growth, margin pressure, and reduced full-year guidance.SCSC
Q2 2026 - Sales fell but margins and cash flow improved; acquisitions and hybrid strategy support growth.SCSC
Q4 2024